Genitourinary Cancers | Specialty

Monitoring for Treatment Response in Advanced Bladder Cancer

December 28th 2017

Frontline Immunotherapy in Advanced Bladder Cancer

December 28th 2017

First-Line Chemotherapy in Advanced Bladder Cancer

December 28th 2017

Advanced Bladder Cancer: Predicting Clinical Response

December 28th 2017

Impact of Immunotherapy in Advanced Bladder Cancer

December 28th 2017

Dr. Pal on the Mutational Burden in Bladder Cancer

December 27th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Dr. Voss on the Future of Clinical Trials for Kidney Cancer

December 26th 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

Role of PARP Inhibitors Developing in mCRPC

December 26th 2017

Alicia Morgan, MD, discusses the role of PARP inhibitors as a novel treatment strategy for patients with metastatic castration-resistant prostate cancer.

FDA Grants Frontline Avelumab/Axitinib Breakthrough Designation for RCC

December 21st 2017

The FDA has granted the PD-L1 inhibitor avelumab a breakthrough therapy designation for use in combination with the VEGF inhibitor axitinib in treatment-naïve patients with advanced renal cell carcinoma.

Future of Bladder Cancer Likely to Be Combination Immunotherapy

December 21st 2017

Arjun Balar, MD, discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.

FDA Grants Apalutamide Priority Review for Nonmetastatic CRPC

December 21st 2017

The FDA has granted a priority review to a new drug application for apalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Apolo on Toxicity Challenges With Checkpoint Inhibitors in Bladder Cancer

December 21st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.

Dr. McKay on FDA Approval of Frontline Cabozantinib in RCC

December 20th 2017

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).

FDA Approves Frontline Cabozantinib for Advanced RCC

December 20th 2017

The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma.

Pembrolizumab Investigated as Adjuvant RCC Therapy

December 18th 2017

Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.

Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer

December 14th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Dr. McDermott on Single-Agent Nivolumab in RCC

December 14th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single-agent for the treatment of patients with renal cell carcinoma.

A Practice Model Designed to Reward Physician Partners Equally

December 14th 2017

Associated Medical Professionals of New York, a urology and radiation oncology practice, seeks to give its physician partners an equal share of its financial success while rewarding all staff members according to their levels of responsibility and workflow intensity.

FDA Grants Nivolumab/Ipilimumab Priority Review for RCC

December 14th 2017

The FDA has granted a priority review to a sBLA for use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.

Apolo Discusses Managing Immune-Related Toxicities in Bladder Cancer

December 14th 2017

Andrea Apolo, MD, discusses the management of immune-related adverse events in the treatment of bladder cancer.